Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 11(1): 6231, 2021 03 18.
Article in English | MEDLINE | ID: mdl-33737648

ABSTRACT

The intestinal microbiome changes dynamically in early infancy. Colonisation by Bifidobacterium and Bacteroides and development of intestinal immunity is interconnected. We performed a prospective observational cohort study to determine the influence of antibiotics taken by the mother immediately before delivery on the intestinal microbiome of 130 healthy Japanese infants. Faecal samples (383) were collected at 1, 3, and 6 months and analysed using next-generation sequencing. Cefazolin was administered before caesarean sections, whereas ampicillin was administered in cases with premature rupture of the membranes and in Group B Streptococcus-positive cases. Bifidobacterium and Bacteroides were dominant (60-70% mean combined occupancy) at all ages. A low abundance of Bifidobacterium was observed in infants exposed to antibiotics at delivery and at 1 and 3 months, with no difference between delivery methods. A lower abundance of Bacteroides was observed after caesarean section than vaginal delivery, irrespective of antibiotic exposure. Additionally, occupancy by Bifidobacterium at 1 and 3 months and by Bacteroides at 3 months differed between infants with and without siblings. All these differences disappeared at 6 months. Infants exposed to intrapartum antibiotics displayed altered Bifidobacterium abundance, whereas abundance of Bacteroides was largely associated with the delivery method. Existence of siblings also significantly influenced the microbiota composition of infants.


Subject(s)
Bacteroides/genetics , Bifidobacterium/genetics , Cesarean Section , Gastrointestinal Microbiome/genetics , Pregnancy Complications, Infectious/microbiology , Streptococcal Infections/microbiology , Ampicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacteroides/isolation & purification , Bifidobacterium/isolation & purification , Cefazolin/therapeutic use , Delivery, Obstetric/methods , Feces/microbiology , Female , Humans , Infant , Infant, Newborn , Intestines/microbiology , Japan , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Prospective Studies , Siblings , Streptococcal Infections/drug therapy
2.
Sci Rep ; 10(1): 7591, 2020 05 05.
Article in English | MEDLINE | ID: mdl-32372037

ABSTRACT

Bifidobacterium species are known to fulfill important functions within the human colon. Thus, stimulating the activity of bifidobacteria is important to maintain host health. We revealed that culture supernatants of Bacillus subtilis C-3102 (referred to as C-3102) stimulated the growth of Bifidobacterium species. In this study, we isolated and identified six bifidogenic growth factors, which were cyclo (D-Val-D-Ile), cyclo (L-Val-D-Ile), cyclo (D-Val-L-Ile), cyclo (L-Val-L-Ile), cyclo (D-Val-L-Leu) and cyclo (L-Val-L-Leu). These six cyclic dipeptides increased the growth of Bifidobacterium species and had no effect on potentially harmful gut organisms. Moreover, supplementation with a mixture of these six cyclic dipeptides significantly increased the abundance of microorganisms related to the genus Bifidobacterium in a human colonic microbiota model culture system, although supplementation with a single type of dipeptide had no effect. These results show that cyclic dipeptides containing Val-Leu and Val-Ile produced by C-3102 could serve as bifidogenic growth factors in the gut microbial community.


Subject(s)
Bacillus subtilis/metabolism , Colon , Gastrointestinal Microbiome , Peptides, Cyclic/biosynthesis , Bacillus subtilis/drug effects , Bifidobacterium/drug effects , Bifidobacterium/growth & development , Chromatography, Liquid , Fermentation , Humans , Peptides, Cyclic/analysis , Peptides, Cyclic/pharmacology , Tandem Mass Spectrometry
3.
Biosci Biotechnol Biochem ; 73(9): 2145-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19734647

ABSTRACT

We developed the AAV-Oxtr-IRES-Venus vector to rescue the oxytocin receptor (Oxtr) gene functionally at restricted regions in the brains of Oxtr knockout mice. First we chose human eIF4G gene-derived IRES to co-express Venus, a fluorescent marker gene, with Oxtr. With selected human eIF4G IRES, we constructed the AAV-Oxtr-IRES-Venus vector, and it caused expression of the Venus gene in the brain when 1 microl of viral solution (9.4x10(7) vg) was injected into the medial amygdaloid nucleus. In primary neuronal cells transduced with this viral vector and followed by oxytocin administration, functional expression of OXTR was detected by Ca(2+) imaging assay.


Subject(s)
Dependovirus/genetics , Eukaryotic Initiation Factor-4G/genetics , Genetic Vectors , Receptors, Oxytocin/genetics , Ribosomes/metabolism , Animals , Base Sequence , DNA Primers , Fluorescence , HeLa Cells , Humans , Mice , Mice, Knockout
SELECTION OF CITATIONS
SEARCH DETAIL
...